Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 8/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | CXCR2 | P25025 | 4/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.38 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.38 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.38 |
| ▸ | KDR | P35968 | 3/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25042804 | 0.77 | AKR1C3 (0.49) | AKR1C3AKR1C2FLT3KDREPHX2 | |
| SCHEMBL24879916 | 0.76 | EPHX2 (0.49) | LIPEEPHX2 | |
| SCHEMBL21054966 | 0.75 | AKR1C3 (0.53) | LIPEAKR1C3AKR1C2EPHX2 | |
| SCHEMBL21055013 | 0.73 | LIPE (0.48) | LIPEAKR1C3AKR1C2 | |
| SCHEMBL12590914 | 0.71 | AKR1C3 (0.53) | LIPEAKR1C3AKR1C2 | |
| SCHEMBL21054435 | 0.70 | LIPE (0.45) | LIPEAKR1C3AKR1C2KDR | |
| SCHEMBL29074784 | 0.69 | KDM4E (0.41) | LIPEAKR1C3AKR1C2KDRPDGFRB | |
| SCHEMBL23152181 | 0.69 | LIPE (0.42) | LIPE | |
| SCHEMBL18748515 | 0.69 | KIF11 (0.44) | LIPEAKR1C3AKR1C2 | |
| SCHEMBL5529908 | 0.68 | EGFR (0.39) | LIPECXCR2KDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023016562-A1 | POLYCYCLIC COMPOUND AND USE THEREOF | 浙江同源康医药股份有限公司 | 2023-02-16 | — | — | WO | disclosed |